The effects of mindfulness on older adults with mild cognitive impairment

The effects of mindfulness on the cognitive function, psychological health, mindfulness and functional abilities in activities of daily living of older adults with mild cognitive impairment.

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12614000820606

Enrollment

Registered

2014-08-01

Start date

2015-09-07

Completion date

2016-01-28

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study aims to investigate whether mindfulness practice can improve the cognitive function, psychological health, mindfulness level and functional abilities in activities of daily living of persons with MCI over time. Furthermore, it will address the issues about the way in which the MCI participants and familiar support persons engage with the mindfulness training program, the nature of group interactions during the program, their program experience and expectations about mindfulness practice, the perceived effects of mindfulness on them, and the MCI participants’ challenges in practising mindfulness.

Interventions

The mindfulness training program will be customised for persons with mild cognitive impairment. It is a 8-week group program delivered by mindfulness experts once weekly for 1.5 hour each session.

Study design

Allocation

Non-randomised trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

60 Years to No maximum

Healthy volunteers

Inclusion criteria

i. Clinical diagnosis of Mild Cognitive Impairment; ii. Must be able to give informed consent to participate by signing the Consent Form; and iii. At least 60 years old.

Exclusion criteria

i. Current active/past significant experience with meditation or yoga; ii. Current use of prescribed cognitive intervention or electromagnetic stimulation; iii. Acquired/Traumatic brain injury; iv. Started new neurological/psychoactive medication within 3 months prior to the first data collection session; v. Current intake of drugs that significantly alter cognition; vi. Illicit drug/alcohol abuse or dependence within the previous 5 years; vii. Current intake of cholinesterase inhibitors; viii. Current severe psychiatric condition; or neurological/cerebrovascular condition; or chronic medical condition that requires intensive medical treatment and monitoring; or advanced cognitive decline; ix. Major impairments in eyesight, hearing or upper limb motor movements; or x. English language difficulties.

Outcome results